Strengths of this risk prediction model for Barrett's includes the relatively large number of cases
A thoughtful commentary on the strengths and weakness of the recent clinical trial of PPI and aspirin.
Nat Rev Clin Oncol. 2018 Dec;15(12):728-730. doi: 10.1038/s41571-018-0096-x.
Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin.
Husain NS1,2, El-Serag HB3,4.
Chemoprevention for patients with Barrett’s oesophagus remains a
controversial topic. Results of the first randomized trial of chemoprevention
using a proton pump inhibitor with or without aspirin were recently reported.
We highlight strengths and weaknesses in the design of the trial and discuss
the clinical implications of the findings.